Front Endocrinol (Lausanne) April 2023 PMID 37077349

Drugs against metabolic diseases as potential senotherapeutics for aging-related respiratory diseases.

Sachi Matsubayashi, Saburo Ito, Jun Araya, Kazuyoshi Kuwano

Full text PDF Download social card

Mentions

Peak: 2 in Apr 2023

across 2 sources since Apr 2023

Extended reach

47,451

potential audience

Total likes

Video views

Mentions per month

Apr 2023 – Jul 2023

Where it's discussed

X / Twitter2 posts
YouTube1 videos

AI synopsis

What people are saying

The discussions reflect a cautious optimism about the article, with phrases like 'recent advances' and 'potential' indicating interest without definitive conclusions. The tone suggests curiosity about new strategies, such as inhalation methods, but stops short of strong endorsement or critique, highlighting a generally supportive yet exploratory attitude.

AgreementModerate agreement

The posts generally acknowledge the potential of using metabolic disease drugs for respiratory aging, showing support and interest.

InterestModerate interest

Discussion appears moderately interested, with mentions of new developments, but lacking deep technical engagement.

EngagementModerate engagement

Posts mention key concepts like senotherapy and inhalation delivery, indicating some level of engagement, but not extensively detailed.

ImpactNeutral impact

The overall impact seems moderate, recognizing the research's significance but not asserting it as a game-changing breakthrough.

Abstract in brief

Recent research suggests that drugs used for metabolic diseases, like metformin and statins, may also help treat aging-related respiratory illnesses such as COPD and IPF by targeting cellular senescence.
Senotherapy, which includes senolytics and senomorphics, aims to eliminate senescent cells or reduce their harmful effects, offering a new approach to manage chronic aging-related diseases.
Delivering these drugs through inhalation could be a promising method to increase their effectiveness in the lungs while minimizing side effects, opening new possibilities for treating respiratory diseases associated with aging.]

Read the full abstract